Evidence map›Paper›PMID 21742946›Full record

Trial reportCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2011

Estrogen levels in nipple aspirate fluid and serum during a randomized soy trial.

Gertraud Maskarinec, Nicholas J Ollberding, Shannon M Conroy, Yukiko Morimoto, Ian S Pagano, Adrian A Franke, Elisabet Gentzschein, Frank Z Stanczyk

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Gertraud MaskarinecUniversity of Hawaii Cancer Center, 1236 Lauhala Street, Honolulu, HI 96813, USA. gertraud@cc.hawaii.edu
Nicholas J Ollberding
Shannon M Conroy
Yukiko Morimoto
Ian S Pagano
Adrian A Franke
Elisabet Gentzschein
Frank Z Stanczyk
University of Hawaii System · USUniversity of Hawaiʻi at Mānoa · USUniversity of Southern California · USCancer Center of Hawaii · US

Funding

University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2M
Nutritional & Behavioral Cancer Prevention in a Multiethnic PopulationR25CA090956 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI MASKARINEC, GERTRAUD · 2002 to 2012
$5.1M
SOY EFFECTS ON ESTROGENS AND MAMMOGRAPHIC DENSITIESR01CA080843 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI MASKARINEC, GERTRAUD · 1999 to 2010
$2.9M
MASS SPECT SYST: SOY PHYTOESTROGEN &CARDIOVASCULAR EFFECTS, ATHEROSCLEROSISS10RR020890 · NCRR · UNIVERSITY OF HAWAII AT MANOA · PI FRANKE, ADRIAN A · 2005 to 2005
$421k
NCI NIH HHS P30 CA071789NCI NIH HHS P30 CA71789NCI NIH HHS R01 CA080843NCI NIH HHS R01 CA80843NCI NIH HHS R25 CA090956NCI NIH HHS R25 CA90956NCRR NIH HHS S10 RR020890
6 · The paper itself

Abstract

backgroundOn the basis of hypothesized protective effect, we examined the effect of soy foods on estrogens in nipple aspirate fluid (NAF) and serum, possible indicators of breast cancer risk.

methodsIn a crossover design, we randomized 96 women who produced 10 μL or more NAF to a high- or low-soy diet for 6 months. During the high-soy diet, participants consumed 2 soy servings of soy milk, tofu, or soy nuts (∼50 mg of isoflavones per day); during the low-soy diet, they maintained their usual diet. Six NAF samples were obtained using a FirstCyte aspirator. Estradiol (E(2)) and estrone sulfate (E(1)S) were assessed in NAF and estrone (E(1)) in serum only, using highly sensitive radioimmunoassays. Mixed-effects regression models accounting for repeated measures and left-censoring limits were applied.

resultsMean E(2) and E(1)S were lower during the high-soy than the low-soy diet (113 vs. 313 pg/mL and 46 vs. 68 ng/mL, respectively) without reaching significance (P = 0.07); the interaction between group and diet was not significant. There was no effect of the soy treatment on serum levels of E(2) (P = 0.76), E(1) (P = 0.86), or E(1)S (P = 0.56). Within individuals, NAF and serum levels of E(2) (r(s) = 0.37; P < 0.001) but not of E(1)S (r(s) = 0.004; P = 0.97) were correlated. E(2) and E(1)S in NAF and serum were strongly associated (r(s) = 0.78 and r(s) = 0.48; P < 0.001).

conclusionSoy foods in amounts consumed by Asians did not significantly modify estrogen levels in NAF and serum. IMPACT: The trend toward lower estrogen levels in NAF during the high-soy diet counters concerns about adverse effects of soy foods on breast cancer risk.

Indexed as

Soy FoodsAdultCross-Over StudiesDietEstradiolEstroneFemaleHumansMiddle AgedNipple Aspirate FluidPremenopauseRadioimmunoassaySoybean ProteinsEstradiolEstroneestrone sulfateSoybean Proteins

Identifiers

PMID21742946
PMCPMC3169755
OpenAlexW2124488213

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.